KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission

10.1128/AAC.02727-13

Saved in:

Bibliographic Details
Main Authors:	Kuhen, K.L, Chatterjee, A.K, Rottmann, M
Other Authors:	MICROBIOLOGY AND IMMUNOLOGY
Format:	Article
Published:	American Society for Microbiology 2020
Subjects:	antimalarial agent artesunate chloroquine imidazole derivative kaf 156 kaf156 mefloquine piperazine derivative unclassified drug KAF156 animal experiment animal model Anopheles antimalarial activity antimalarial drug susceptibility article controlled study disease elimination dose time effect relation drug dose comparison drug efficacy drug safety female genetic strain human human cell IC 50 in vitro study in vivo study malaria control malaria falciparum mouse multiple drug dose nonhuman parasite clearance parasite transmission Plasmodium falciparum Plasmodium vivax malaria priority journal rodent malaria schizont single drug dose sporozoite treatment response animal drug effects IC50 Institute for Cancer Research mouse Malaria, Falciparum transmission Animals Antimalarials Imidazoles Inhibitory Concentration 50 Mice Mice, Inbred ICR Piperazines Sporozoites
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/180171
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-180171
record_format	dspace
spelling	sg-nus-scholar.10635-1801712024-10-26T00:43:59Z KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission Kuhen, K.L Chatterjee, A.K Rottmann, M MICROBIOLOGY AND IMMUNOLOGY antimalarial agent artesunate chloroquine imidazole derivative kaf 156 kaf156 mefloquine piperazine derivative unclassified drug antimalarial agent imidazole derivative KAF156 piperazine derivative animal experiment animal model Anopheles antimalarial activity antimalarial drug susceptibility article controlled study disease elimination dose time effect relation drug dose comparison drug efficacy drug safety female genetic strain human human cell IC 50 in vitro study in vivo study malaria control malaria falciparum mouse multiple drug dose nonhuman parasite clearance parasite transmission Plasmodium falciparum Plasmodium vivax malaria priority journal rodent malaria schizont single drug dose sporozoite treatment response animal drug effects IC50 Institute for Cancer Research mouse Malaria, Falciparum transmission Animals Antimalarials Imidazoles Inhibitory Concentration 50 Malaria, Falciparum Mice Mice, Inbred ICR Piperazines Plasmodium falciparum Sporozoites 10.1128/AAC.02727-13 Antimicrobial Agents and Chemotherapy 58 9 5060-5067 2020-10-26T07:20:52Z 2020-10-26T07:20:52Z 2014 Article Kuhen, K.L, Chatterjee, A.K, Rottmann, M (2014). KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrobial Agents and Chemotherapy 58 (9) : 5060-5067. ScholarBank@NUS Repository. https://doi.org/10.1128/AAC.02727-13 0066-4804 https://scholarbank.nus.edu.sg/handle/10635/180171 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ American Society for Microbiology Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	antimalarial agent artesunate chloroquine imidazole derivative kaf 156 kaf156 mefloquine piperazine derivative unclassified drug antimalarial agent imidazole derivative KAF156 piperazine derivative animal experiment animal model Anopheles antimalarial activity antimalarial drug susceptibility article controlled study disease elimination dose time effect relation drug dose comparison drug efficacy drug safety female genetic strain human human cell IC 50 in vitro study in vivo study malaria control malaria falciparum mouse multiple drug dose nonhuman parasite clearance parasite transmission Plasmodium falciparum Plasmodium vivax malaria priority journal rodent malaria schizont single drug dose sporozoite treatment response animal drug effects IC50 Institute for Cancer Research mouse Malaria, Falciparum transmission Animals Antimalarials Imidazoles Inhibitory Concentration 50 Malaria, Falciparum Mice Mice, Inbred ICR Piperazines Plasmodium falciparum Sporozoites
spellingShingle	antimalarial agent artesunate chloroquine imidazole derivative kaf 156 kaf156 mefloquine piperazine derivative unclassified drug antimalarial agent imidazole derivative KAF156 piperazine derivative animal experiment animal model Anopheles antimalarial activity antimalarial drug susceptibility article controlled study disease elimination dose time effect relation drug dose comparison drug efficacy drug safety female genetic strain human human cell IC 50 in vitro study in vivo study malaria control malaria falciparum mouse multiple drug dose nonhuman parasite clearance parasite transmission Plasmodium falciparum Plasmodium vivax malaria priority journal rodent malaria schizont single drug dose sporozoite treatment response animal drug effects IC50 Institute for Cancer Research mouse Malaria, Falciparum transmission Animals Antimalarials Imidazoles Inhibitory Concentration 50 Malaria, Falciparum Mice Mice, Inbred ICR Piperazines Plasmodium falciparum Sporozoites Kuhen, K.L Chatterjee, A.K Rottmann, M KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
description	10.1128/AAC.02727-13
author2	MICROBIOLOGY AND IMMUNOLOGY
author_facet	MICROBIOLOGY AND IMMUNOLOGY Kuhen, K.L Chatterjee, A.K Rottmann, M
format	Article
author	Kuhen, K.L Chatterjee, A.K Rottmann, M
author_sort	Kuhen, K.L
title	KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
title_short	KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
title_full	KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
title_fullStr	KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
title_full_unstemmed	KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
title_sort	kaf156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
publisher	American Society for Microbiology
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/180171
_version_	1821212319847284736

KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission

Similar Items